Targets › GRIN2A
55 programs from 54 companies in 110 trials: 40 Phase 2, 27 Phase 4, 22 Phase 1, 21 Phase 3; Psychiatry, Neurology, Other; next expected readout Nov 2026.
Component of N-methyl-D-aspartate (NMDA) receptors (NMDARs) that function as heterotetrameric, ligand-gated cation channels with high calcium permeability and voltage-dependent block by Mg(2+). NMDARs participate in synaptic plasticity for learning and memory formation by contributing to the slow phase of excitatory postsynaptic current, long-term synaptic potentiation, and learning (By similarity). (UniProt, Q12879)
Open in Phaseline: the race on GRIN2A, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Stanford University | Ketamine Hydrochloride Glutamate [NMDA] receptor negative allosteric modulator | GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3B | Phase 4 | Chronic Pain; Obsessive-Compulsive Disorder; Epilepsy; Psychiatric Disorder | Nov 2026 |
| University of Puerto Rico | Esketamine Hydrochloride Glutamate [NMDA] receptor negative allosteric modulator | GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3B | Phase 4 | Treatment-resistant Depression (TRD) | Dec 2026 |
| National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Acamprosate calcium Glutamate [NMDA] receptor antagonist; GABA-A receptor; anion channel positive modulator | GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3B | Phase 4 | Alcohol Use Disorder | Dec 2026 |
| University of Oklahoma | Ketamine Glutamate [NMDA] receptor negative allosteric modulator | GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3B | Phase 4 | Laceration of Skin; Hemorrhoids | Jan 2027 |
| Ain Shams University | Ketamine Glutamate [NMDA] receptor negative allosteric modulator | GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3B | Phase 4 | Intraoperative Awareness; Perioperative Analgesia; Sedation and Analgesia; Inhalation Anesthesia | Feb 2027 |
| Margaux M. Salas, PhD | Ketamine Glutamate [NMDA] receptor negative allosteric modulator | GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3B | Phase 4 | Neuropathic Pain | May 2027 |
| Universidad de Antioquia | Ketamine Glutamate [NMDA] receptor negative allosteric modulator | GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3B | Phase 4 | Pain, Postoperative | Jun 2027 |
| Icahn School of Medicine at Mount Sinai | Ketamine Glutamate [NMDA] receptor negative allosteric modulator | GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3B | Phase 4 | Major Depressive Disorder; Depression | Aug 2027 |
| Massachusetts General Hospital | Ketamine Glutamate [NMDA] receptor negative allosteric modulator | GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3B | Phase 4 | Major Depressive Disorder; Depression | Jun 2030 |
| CSPC Ouyi Pharmaceutical | Dextromethorphan Sigma opioid receptor agonist; Glutamate [NMDA] receptor subunit epsilon 1 antagonist | SIGMAR1, GRIN2A | Phase 3 | Major Depressive Disorder (MDD) | Dec 2026 |
| University Health Network, Toronto | Ketamine hydrochloride Glutamate [NMDA] receptor negative allosteric modulator | GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3B | Phase 3 | Chronic Daily Headache; Major Depressive Disorder | Feb 2027 |
| Nantes University Hospital | Ketamine Glutamate [NMDA] receptor negative allosteric modulator | GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3B | Phase 3 | Rapid Sequence Induction | Apr 2027 |
| Canadian Cancer Trials Group | Memantine Glutamate [NMDA] receptor negative allosteric modulator | GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3B | Phase 3 | Brain Metastases | Jun 2027 |
| State University of New York at Buffalo | Ketamine Glutamate [NMDA] receptor negative allosteric modulator | GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3B | Phase 3 | Distal Radius Fracture Reduction | Aug 2027 |
| Children's Oncology Group | Memantine Hydrochloride Glutamate [NMDA] receptor negative allosteric modulator | GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3B | Phase 3 | Central Nervous System Carcinoma | Sep 2027 |
| Assistance Publique - Hôpitaux de Paris | Ketamine Glutamate [NMDA] receptor negative allosteric modulator | GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3B | Phase 3 | Major Depressive Episode; Limb Injury | Feb 2028 |
| Meyer Children's Hospital IRCCS | L-serine Amino acid supplementation to support GRIN-related neurodevelopmental disorders caused by | GRIN1, GRIN2A, GRIN2B, GRIN2D | Phase 3 | GRIN-related Disorders | Jun 2028 |
| Dr. Inge Winter | Esketamine hydrochloride Glutamate [NMDA] receptor negative allosteric modulator | GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3B | Phase 3 | Major Depressive Disorder | Jun 2028 |
| Johnson & Johnson (Janssen) | Esketamine Glutamate [NMDA] receptor negative allosteric modulator | GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3B | Phase 3 | Depressive Disorder, Treatment-Resistant; Depressive Disorder, Major; Sleep Wake Disorders; Prenatal Depression … | Dec 2028 |
| Yale University | ketamine hydrochloride Glutamate [NMDA] receptor negative allosteric modulator | GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3B | Phase 3 | Depression; Parkinson's Disease; Posttraumatic Stress Disorder; Depressive Disorder, Major | Jan 2029 |
| Tata Memorial Centre | Memantine Glutamate [NMDA] receptor negative allosteric modulator | GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3B | Phase 3 | Neurocognitive Dysfunction | Jan 2031 |
| NRG Oncology | Memantine Hydrochloride Glutamate [NMDA] receptor negative allosteric modulator | GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3B | Phase 3 | Metastatic Lung Small Cell Carcinoma | Jul 2031 |
| Reinier de Graaf Groep | Esketamine hydrochloride Glutamate [NMDA] receptor negative allosteric modulator | GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3B | Phase 3 | Endometriosis | – |
| NYU Langone Health | Ketamine Glutamate [NMDA] receptor negative allosteric modulator | GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3B | Phase 3 | Chronic Postsurgical Pain | – |
| Dr. med. Marcus Herdener | Ketamine Glutamate [NMDA] receptor negative allosteric modulator | GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3B | Phase 2 | Cocaine Use Disorder; Alcohol Abuse/Dependence | Dec 2026 |
| University of Virginia | Memantine Hydrochloride Glutamate [NMDA] receptor negative allosteric modulator | GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3B | Phase 2 | Alzheimer Disease | Dec 2026 |
| The University of Texas Health Science Center at San Antonio | Ketamine Hydrochloride Glutamate [NMDA] receptor negative allosteric modulator | GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3B | Phase 2 | Suicide; Suicidal Ideation | Dec 2026 |
| National Institute of Mental Health (NIMH) | Ketamine Hydrochloride Glutamate [NMDA] receptor negative allosteric modulator | GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3B | Phase 2 | Healthy Volunteers; Healthy Volunteer; Depression | Jan 2027 |
| Case Comprehensive Cancer Center | Memantine Glutamate [NMDA] receptor negative allosteric modulator | GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3B | Phase 2 | Brain Metastases | May 2027 |
| University of Chicago | Memantine Glutamate [NMDA] receptor negative allosteric modulator | GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3B | Phase 2 | Skin-Picking | Jun 2027 |
| Shanghai Mental Health Center | Memantine Glutamate [NMDA] receptor negative allosteric modulator | GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3B | Phase 2 | Obsessive-Compulsive Disorder | Jun 2027 |
| Christian Hassager | esketamine hydrochloride Glutamate [NMDA] receptor negative allosteric modulator | GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3B | Phase 2 | Out-of-hospital Cardiac Arrest (OHCA) | Sep 2027 |
| Syndeio Biosciences | Zelquistinel Positive allosteric modulator of the N-Methyl-D-Aspartate (NMDA) receptor | GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D | Phase 2 | Major Depressive Disorder; Healthy Volunteers in Fed and Fasted State | Sep 2027 |
| University of Pennsylvania | Amantadine Glutamate [NMDA] receptor antagonist; Matrix protein 2 inhibitor | GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3B | Phase 2 | Stroke, Ischemic | Dec 2027 |
| Haukeland University Hospital | D-serine NMDAR co-agonist; modulates N-methyl-D-aspartate receptor function | GRIN1, GRIN2A, GRIN2B | Phase 2 | Parkinson s Disease | Mar 2028 |
| Medical College of Wisconsin | Memantine Glutamate [NMDA] receptor negative allosteric modulator | GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3B | Phase 2 | Brain Metastases | May 2028 |
| Inova Health Care Services | Memantine Hydrochloride Glutamate [NMDA] receptor negative allosteric modulator | GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3B | Phase 2 | Hepatocellular Carcinoma | Jul 2028 |
| University of Maryland, Baltimore | Ketamine Glutamate [NMDA] receptor negative allosteric modulator | GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3B | Phase 2 | Opioid Use Disorder | Aug 2028 |
| VA Office of Research and Development | Ketamine hydrochloride Glutamate [NMDA] receptor negative allosteric modulator | GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3B | Phase 2 | Chronic Low Back Pain; Parkinson's Disease | Dec 2028 |
| Exciva | Dextromethorphan (EXV-802) Sigma opioid receptor agonist; Glutamate [NMDA] receptor subunit epsilon 1 antagonist | SIGMAR1, GRIN2A | Phase 2 | Agitation Associated With Alzheimer's Disease Dementia; Obsessive-Compulsive Disorder; Hodgkin Lymphoma; Psychedelic Effects in Healthy Volunteers … | Jan 2029 |
| UNC Lineberger Comprehensive Cancer Center | Memantine Glutamate [NMDA] receptor negative allosteric modulator | GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3B | Phase 2 | Breast Cancer | Jun 2029 |
| Samer Gawrieh | Acamprosate Glutamate [NMDA] receptor antagonist; GABA-A receptor; anion channel positive modulator | GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3B | Phase 2 | Alcohol-associated Hepatitis | Dec 2029 |
| The University of Texas Health Science Center at San Antonio | Memantine Glutamate [NMDA] receptor negative allosteric modulator | GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3B | Phase 2 | Brain Tumor | Jul 2030 |
| University of Edinburgh | Amantadine Glutamate [NMDA] receptor antagonist; Matrix protein 2 inhibitor | GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3B | Phase 2 | Motor Neuron Disease, Amyotrophic Lateral Sclerosis | Dec 2030 |
| SHINKEI Therapeutics | Amantadine Hydrochloride (MR-301) Glutamate [NMDA] receptor antagonist; Matrix protein 2 inhibitor | GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3B | Phase 2 | Traumatic Brain Injury | – |
| Sohag University | Ketamine Glutamate [NMDA] receptor negative allosteric modulator | GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3B | Phase 2 | Generalized Convulsive Status Epilepticus; Convulsive Status EPILEPTICUS | – |
| Children's Hospital Medical Center, Cincinnati | Memantine Glutamate [NMDA] receptor negative allosteric modulator | GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3B | Phase 2 | Fragile X Syndrome | – |
| The Alfred | NMDA receptor antagonist NMDA receptor antagonist | GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D | Phase 2 | Borderline Personality Disorder | – |
| Aptinyx | NYX-458 NMDAR modulator | GRIN1, GRIN2A, GRIN2B | Phase 2 | Mild Cognitive Impairment | – |
| University of Zurich | Memantine Glutamate [NMDA] receptor negative allosteric modulator | GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3B | Phase 1 | Glioblastoma | Dec 2026 |
| Bjorn H. Ebdrup | Memantine Glutamate [NMDA] receptor negative allosteric modulator | GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3B | Phase 1 | Psychosis | Dec 2026 |
| Washington University School of Medicine | Nitrous Oxide NMDA receptor antagonist | GRIN1, GRIN2A, GRIN2B | Phase 1 | Depressive Disorder, Major | Apr 2027 |
| Jeffrey Miller | Memantine Glutamate [NMDA] receptor negative allosteric modulator | GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3B | Phase 1 | Major Depressive Disorder (MDD) | Jun 2027 |
| National Institute of Neurological Disorders and Stroke (NINDS) | Acamprosate calcium Glutamate [NMDA] receptor antagonist; GABA-A receptor; anion channel positive modulator | GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3B | Phase 1 | Amyotrophic Lateral Sclerosis | Sep 2027 |
| University of Utah | Ketamine Glutamate [NMDA] receptor negative allosteric modulator | GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3B | Phase 1 | Opioid-use Disorder; Pain | Dec 2027 |
Major Depressive Disorder (9) Depression (4) Brain Metastases (3) Depressive Disorder, Major (3) Obsessive-Compulsive Disorder (3) Hepatocellular Carcinoma (2) Opioid Use Disorder (2) Parkinson's Disease (2) Pain, Postoperative (2) Rapid Sequence Induction (2) Neuropathic Pain (2) Major Depressive Disorder (MDD) (2)
small molecule (48), protein or peptide (2), mixed (2)
The University of Texas Health Science Center at San Antonio (2) The Alfred (1) Reinier de Graaf Groep (1) Christian Hassager (1) Syndeio Biosciences (1) Massachusetts General Hospital (1) Samer Gawrieh (1) Children's Oncology Group (1) Tata Memorial Centre (1) University of Zurich (1) Dr. med. Marcus Herdener (1) Medical College of Wisconsin (1) Ain Shams University (1) National Institute of Mental Health (NIMH) (1) SHINKEI Therapeutics (1) University of Oklahoma (1) Assistance Publique - Hôpitaux de Paris (1) Icahn School of Medicine at Mount Sinai (1) Aptinyx (1) University of Puerto Rico (1)
GRIN1 (53) GRIN2B (53) GRIN2D (50) GRIN3B (47) GRIN2C (2) SIGMAR1 (2)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.